TABLE 5.

Serological patterns and EBV diagnoses for the 1,846 study patients using only BioPlex VCA IgG, VCA IgM, and heterophile antibody assay results

Pattern designation	“Presumed” EBV diagnosis	BioPlex resultb			No. of patients							Predictive value (%)f
					In study	With EBV diagnosis based on medical record reviewc					Not reviewed
		VCA IgG	VCA IgM	Het IgM		EBV naive	Primary acute	Past infection	Recovery/reactivation	Inconclusive
A	EBV naive	Neg	Neg	Neg	438	76	2	12	1	28	319d	63.9
B	Primary acute	Neg	Pos	Pos	34	0	31	0	1	2	0	91.2
C	Primary acute	Neg	Pos	Neg	27	7	10	4	1	2	3e	41.7
D	Primary acute	Neg	Neg	Pos	4	0	3	0	0	1	0	75.0
E	Past infection	Pos	Neg	Neg	1,243	6	2	431	2	84	718d	82.1
F	Recov/Reacta	Pos	Pos	Neg	90	2	3	65	3	17	0	N/Cg
G	Recov/React	Pos	Pos	Pos	10	0	5	3	1	1	0	N/C
H	Recov/React	Pos	Neg	Pos	0	0	0	0	0	0	0	N/C
Total					1,846	91	56	515	9	135	1,040

^aRecov/React, recovery/reactivation: those patients who are in a late acute infection stage or have benign reactivation.

^bPos, positive; Neg, negative.

^cSee Materials and Methods for classification of EBV stage. Areas of expected concordance between “Presumed” and observed EBV stage are highlighted in bold.

^dRecords of a percentage of randomly selected patients were reviewed (see Table 2).

^ePatients were not reviewed due to unavailability of the medical record.

^fPredictive value calculated by dividing the number of patients in the shaded box by the total number of patients with completed chart review in that row.

^gN/C, not calculated. See Results and Discussion.